Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of fosfluridine tidoxil in advanced breast and colorectal cancer
2005-001680-57Phase 2Completed
- Sponsor
- Heidelberg Pharma AG
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosfluridine tidoxil in breast cancer and metastatic colon cancer (mCRC), sponsored by Heidelberg Pharma AG. Primary endpoints: Objective tumor response rate on target lesions and Objective tumor response rate on non-target lesions. Started Aug 2005; status: completed.
02
Drugs
fosfluridine tidoxil
03
Conditions
breast cancermetastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2005-001680-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001680-57.